- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00867464
Uitgebreide follow-up van jonge vrouwen in Costa Rica die een vaccin kregen voor humaan papillomavirus type 16 en 18 en niet-gevaccineerde controles
Uitgebreide follow-up van jonge vrouwen in Costa Rica die zijn gevaccineerd tegen humaan papillomavirus type 16 en 18 en niet-gevaccineerde controles
This research trial studies extended follow up of young women in Costa Rica who received vaccine for human papillomavirus types 16 and 18 and unvaccinated controls. Collecting information from young women in Costa Rica who have received vaccine for human papillomavirus types 16 and 18 and a new group of unvaccinated controls enrolled for the follow-up period, may help doctors learn more about the risks and benefits of prophylactic human papillomavirus vaccine.
Studie Overzicht
Toestand
Conditie
Gedetailleerde beschrijving
PRIMARY OBJECTIVES:
I. To evaluate the 10-year global impact of human papillomavirus (HPV)-16/18 vaccination of young adult women.
II. To evaluate determinants of the immune response to HPV and the vaccine, and markers of long-term protection.
III. To evaluate the natural history of HPV and cervical disease in vaccinated and unvaccinated populations.
OUTLINE:
Participants undergo long term follow-up comprising risk factor questionnaire, pelvic examination for all sexually experienced women, and specimen collection at years 6, 8, and 10.
Studietype
Inschrijving (Geschat)
Contacten en locaties
Studie Locaties
-
-
Guanacaste Province
-
Liberia, Guanacaste Province, Costa Rica, 50101
- Agencia Costarricense de Investigaciones Biomédicas (ACIB)
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Kind
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
Young women in Costa Rica who received vaccination against human papillomavirus types 16 and 18 and unvaccinated controls.
Beschrijving
Inclusion Criteria:
- Women who participated in the Costa Rica Vaccine Trial (CVT) and lived in the Guanacaste province and a few areas of Puntarenas closest to Guanacaste will be eligible for the long-term follow up LTFU study
- Women who received the HPV-16/18 vaccine at the start of CVT will be invited for up to 6 years of additional follow-up, and women who were originally in the control arm of CVT and were offered the HPV-16/18 vaccine at crossover will be invited for an additional 2 years of follow-up
- A subset of the control arm women who are in the crossover immunogenicity subcohort will be followed the full 6 years
- Some women who received HPV vaccination and were not invited into the LTFU protocol (stopped attending their screening visits during CVT, discontinued their study participation during CVT or lived outside the study area) will be invited to participate in the LTFU protocol, particularly those who received an incomplete vaccination schedule
- UNVACCINATED CONTROL GROUP:
- Born in or between July 1978 and November 1987
- Residents of Guanacaste Province and a few areas of Puntarenas closest to Guanacaste at some point during 2005
- Able to speak/understand Spanish
- Apparently mentally competent
- Written informed consent obtained prior to enrollment
Exclusion Criteria:
- History of cervical cancer
- History of hysterectomy
- Any important medical condition or other criteria that the investigator considers that precludes enrollment
- Vaccination with Gardasil or Cervarix will be an exclusionary criterion, but few women are expected to have received these vaccines at the time of enrollment; use of these vaccines after enrollment is not a criterion for study interruption but we plan to collect information on vaccination history so that the few women who report having been vaccinated with one of the HPV vaccines after enrollment can be evaluated separately at analysis
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Observatiemodellen: CASE_CONTROL
- Tijdsperspectieven: PROSPECTIVE
Cohorten en interventies
Groep / Cohort |
Interventie / Behandeling |
|---|---|
|
Observational (long term follow-up)
Participants undergo long term follow-up comprising risk factor questionnaire, pelvic examination for all sexually experienced women, and specimen collection at years 6, 8, and 10. |
Correlative studies Ancillary studies Correlative studies
Andere namen:
Undergo extended follow-up
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Cumulative rate of cervical intraepithelial neoplasia 3 (CIN3)
Tijdsspanne: At 10 years
|
Both absolute rate differences and percent reduction in rates will be evaluated. |
At 10 years
|
|
Level of immune response markers as prediction of long-term success of HPV vaccine
Tijdsspanne: Up to 10 years
|
For efficiency, a nested case-control approach is envisioned to evaluate this question. We propose to compare women who become infected against a subset of those who do not (non-failures) with respect to immune response markers of interest. |
Up to 10 years
|
|
Increase in the rate of cervical lesions associated with other carcinogenic HPV types that the vaccine does not protect against from prevention of HPV-16/18 associated cervical lesions through vaccination
Tijdsspanne: Up to 10 years
|
The 10-year cumulative rate of incident CIN2+ associated with HPV types other than HPV-16/18 and closely related HPV types in the alpha-7/9 species for which evidence of vaccine cross-protection is demonstrated will be compared between vaccinated and unvaccinated women. |
Up to 10 years
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Aimee Kreimer, National Cancer Institute (NCI)
Publicaties en nuttige links
Algemene publicaties
- Shing JZ, Hu S, Herrero R, Hildesheim A, Porras C, Sampson JN, Schussler J, Schiller JT, Lowy DR, Sierra MS, Carvajal L, Kreimer AR; Costa Rica HPV Vaccine Trial Group. Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomised Costa Rica HPV Vaccine Trial. Lancet Oncol. 2022 Jul;23(7):940-949. doi: 10.1016/S1470-2045(22)00291-1. Epub 2022 Jun 13.
- Porras C, Tsang SH, Herrero R, Guillen D, Darragh TM, Stoler MH, Hildesheim A, Wagner S, Boland J, Lowy DR, Schiller JT, Schiffman M, Schussler J, Gail MH, Quint W, Ocampo R, Morales J, Rodriguez AC, Hu S, Sampson JN, Kreimer AR; Costa Rica Vaccine Trial Group. Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine Trial. Lancet Oncol. 2020 Dec;21(12):1643-1652. doi: 10.1016/S1470-2045(20)30524-6.
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Geschat)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Urogenitale ziekten
- Genitale ziekten
- Mondziekten
- Stomatognatische ziekten
- Pathologische processen
- Urogenitale neoplasmata
- Neoplasmata per site
- Neoplasmata
- Vrouwelijke urogenitale ziekten
- Vrouwelijke urogenitale ziekten en zwangerschapscomplicaties
- Ziekte attributen
- Darmziekten
- Infecties
- Virusziekten
- Gastro-intestinale neoplasmata
- Neoplasmata van het spijsverteringsstelsel
- Ziekten van het spijsverteringsstelsel
- Gastro-intestinale aandoeningen
- Colorectale neoplasmata
- Intestinale neoplasmata
- Rectale ziekten
- Baarmoeder Ziekten
- Genitale ziekten, vrouw
- Hoofd- en nekneoplasmata
- Overdraagbare ziekten
- Seksueel overdraagbare aandoeningen, viraal
- Seksueel overdraagbare aandoeningen
- DNA-virusinfecties
- Genitale neoplasmata, vrouwelijk
- Baarmoederhalsaandoeningen
- Baarmoeder Neoplasmata
- Tumorvirusinfecties
- Anus Ziekten
- Rectale neoplasmata
- Pathologische aandoeningen, tekenen en symptomen
- Baarmoeder Cervicale Neoplasmata
- Papillomavirus-infecties
- Mond neoplasmata
- Anus Neoplasmata
Andere studie-ID-nummers
- NCI-2016-00231
- NCI-2016-00231 (Register-ID: CTRP (Clinical Trial Reporting Program))
- 999909106
- 09-C-N106 (Andere identificatie: National Cancer Institute)
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .